President and Chief Executive Officer Jim Clemmer joined AngioDynamics in April 2016, bringing more than 25 years of leadership within the healthcare industry and a proven track record of success.

Prior to AngioDynamics, Clemmer served as president of the $1.8 billion medical supplies segment at Covidien plc., where he directed strategic and day-to-day operations for global business divisions that collectively manufactured 23 different product categories. In addition, he managed global manufacturing, research and development, operational excellence, business development and all other functions associated with the medical supplies business. Prior to his role at Covidien, Clemmer served as group president at Kendall Healthcare, where he managed the US business across five divisions and built the strategic plan for the Medical Supplies segment before it was spun off from Tyco. Clemmer began his career at Sage Products, Inc.

Clemmer currently serves on the Board of Directors for AngioDynamics and Lantheus Medical Imaging. Clemmer is a graduate of the Massachusetts College of Liberal Arts. 
 

Stephen A. Trowbridge was appointed Executive Vice President and Chief Financial Officer in February 2020, having served as Interim Chief Financial Officer since October 2019. Prior to his appointment as Chief Financial Officer, he served as the Company’s Senior Vice President and General Counsel. He joined AngioDynamics in June 2008 as Corporate Counsel. 

In addition to serving as the Company’s CFO and managing the finance functions,
Mr. Trowbridge also manages the Legal function on an interim basis. Mr. Trowbridge also oversees the Company’s clinical affairs, medical affairs and healthcare economics departments. Prior to AngioDynamics, Mr. Trowbridge served as Corporate Counsel at Philips Healthcare and Intermagnetics General Corporation. 

Mr. Trowbridge began his career with Cadwalader, Wickersham & Taft LLP in the firm’s Mergers and Acquisitions and Securities Group. Mr. Trowbridge received a Bachelor of Science in Science and Technology Studies from Rensselaer Polytechnic Institute, a Juris Doctor from the University of Pennsylvania Law School, and a Master of Business Administration from Duke University’s Fuqua School of Business.

Chad T. Campbell joined AngioDynamics in May 2016. He is the Senior Vice President and General Manager for AngioDynamics’ Oncology and Interventional Devices Global Business Units. In his role, Mr. Campbell oversees global commercialization of the Oncology and Interventional Devices global business unit portfolios. Mr. Campbell joined AngioDynamics from Medtronic, serving as Vice President of Marketing for the Patient Care and Safety business after serving as the Vice President of Marketing for the SharpSafety business at Covidien (Medtronic). During his tenure at Covidien, Mr. Campbell also held roles including Director of Marketing, Area Vice President of Sales, Region Manager, and other sales & marketing roles. Mr. Campbell received a Bachelor of Arts from the University of Kentucky.

Laura Piccinini joined AngioDynamics as Senior Vice President and General Manager for International in June 2021. Ms. Piccinini brings more than 25 years of experience in leadership roles in the Medical Device/Technology industry, with an extensive background in the field of respiratory care. Most recently, she served as CEO & member of the Board of Directors for Respiratory Motion, Inc., and was Global Head of Commercial Operations for the Implants business unit at Nobel Biocare Systems (Danaher Company/Envista IPO). Earlier in her career, Ms. Piccinini served as President of EMEA at both Covidien and Stryker. Ms. Piccinini is a graduate of the Parma University of Medicine, where she received a nursing degree with specializations in ICU, Anesthesia, and First Aid as a Helicopter Flight Coordinator.